Literature DB >> 17013899

Concomitant chemo-radiotherapy and local dose of radiation as risk factors for second malignant neoplasms after solid cancer in childhood: a case-control study.

Sylvie Guérin1, Catherine Guibout, Akthar Shamsaldin, Marie-Gabrielle Dondon, Ibrahima Diallo, Mike Hawkins, Odile Oberlin, Olivier Hartmann, Jean Michon, Marie-Cécile Le Deley, Florent de Vathaire.   

Abstract

Radiotherapy and chemotherapy are associated with an increased risk of a second malignant neoplasm (SMN) after a cancer during childhood. This study specified the dose-effect relationship between radiotherapy, chemotherapy and the risk of a SMN, and investigated the effect of chemo-radiotherapy on the risk of SMN. A case-control study nested in a European cohort of 4,581 patients treated for a solid cancer during childhood was conducted. One hundred and fifty three cases with a SMN and 442 controls were matched according to sex, age at first cancer, calendar year, type of first cancer and follow-up. The local radiation dose was estimated at the site of the SMN, for each case and at the same site, for the matched controls. The local dose of radiation significantly increased the risk of a SMN. The best model was linear with an excess relative risk per Gray equal to 0.13 (95% CI, 0.06; 0.26). Any chemotherapy significantly increased the risk of a SMN, odd ratio(adjusted) (OR(adjusted)) = 2.4 (95% confidence interval (95% CI), 1.4-4.1), but no dose-effect relationship was observed between any drug category and the risk of a SMN. Patients who had received concomitant chemo-radiotherapy were significantly more at risk of developing a SMN than patients who had been treated with sequential chemo-radiotherapy, even after adjustment for the local dose of radiation and the 6 most frequently administered drugs, OR(adjusted) = 2.3 (95%CI, 1.1-4.8). Radiation was found to be the foremost treatment-related risk factor for the occurrence of a SMN. Compared to sequential treatment, concomitant chemo-radiotherapy may lead to a higher risk of a SMN.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17013899     DOI: 10.1002/ijc.22197

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

1.  Local radiation dose and solid second malignant neoplasms after childhood cancer in Germany: a nested case-control study.

Authors:  Ulrike Hennewig; Peter Kaatsch; Maria Blettner; Claudia Spix
Journal:  Radiat Environ Biophys       Date:  2014-05-27       Impact factor: 1.925

2.  Low- and middle-income countries can reduce risks of subsequent neoplasms by referring pediatric craniospinal cases to centralized proton treatment centers.

Authors:  Phillip J Taddei; Nabil Khater; Bassem Youssef; Rebecca M Howell; Wassim Jalbout; Rui Zhang; Fady B Geara; Annelise Giebeler; Anita Mahajan; Dragan Mirkovic; Wayne D Newhauser
Journal:  Biomed Phys Eng Express       Date:  2018-02-07

3.  Clinical features and outcome of multiple primary malignancies involving hepatocellular carcinoma: a long-term follow-up study.

Authors:  Qing-An Zeng; Jiliang Qiu; Ruhai Zou; Yijie Li; Shengping Li; Binkui Li; Pinzhu Huang; Jian Hong; Yun Zheng; Xiangming Lao; Yunfei Yuan
Journal:  BMC Cancer       Date:  2012-04-17       Impact factor: 4.430

4.  Cisplatin Reduces the Frequencies of Radiotherapy-Induced Micronuclei in Peripheral Blood Lymphocytes of Patients with Gynaecological Cancer: Possible Implications for the Risk of Second Malignant Neoplasms.

Authors:  Aneta Węgierek-Ciuk; Anna Lankoff; Halina Lisowska; Piotr Kędzierawski; Pamela Akuwudike; Lovisa Lundholm; Andrzej Wojcik
Journal:  Cells       Date:  2021-10-09       Impact factor: 6.600

5.  Methodological extensions of meta-analysis with excess relative risk estimates: application to risk of second malignant neoplasms among childhood cancer survivors treated with radiotherapy.

Authors:  Kazutaka Doi; Makiko N Mieno; Yoshiya Shimada; Hidenori Yonehara; Shinji Yoshinaga
Journal:  J Radiat Res       Date:  2014-07-18       Impact factor: 2.724

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.